Candel Therapeutics Announces an Upcoming Presentation at the AACR Annual Meeting Unveiling New Cancer Immunotherapy Candidate
05 Mars 2024 - 10:30PM
Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a
clinical stage biopharmaceutical company focused on developing
multimodal biological immunotherapies to help patients fight
cancer, today announced the Company will present a poster
presentation at the American Association for Cancer Research (AACR)
Annual Meeting taking place April 5-10, 2024, in San Diego, CA. The
presentation will describe the second candidate from the enLIGHTEN™
Discovery Platform, a first-in-class multimodal immunotherapy
candidate for induction of tertiary lymphoid structures as a novel
therapeutic strategy for solid tumors. This abstract presentation
at AACR accelerates the milestone associated with the unveiling of
the second enLIGHTEN™ program, which was originally planned for the
third quarter of 2024.
Presentation details are as follows:
- Presentation Title:
A first-in-class multimodal immunotherapy for induction of tertiary
lymphoid structures as a novel therapeutic strategy for solid
tumors
- Presenter: Anne R.
Diers, PhD, Senior Director, Research, Candel Therapeutics
- Abstract Number:
LB263
- Session Date and
Time: Tuesday, April 9, 2024; 9:00 AM - 12:30 PM PT
- Session Title:
Late-Breaking Research: Experimental and Molecular Therapeutics
3
- Location: San Diego
Convention Center
All regular abstracts are available for viewing via AACR’s
online itinerary planner, located here.
About the enLIGHTEN™ Discovery Platform
The enLIGHTEN™ Discovery Platform is a systematic, iterative
herpes simplex virus (HSV)-based discovery platform leveraging
human biology and advanced analytics to create new multimodal
biological immunotherapies for solid tumors. The enLIGHTEN™
Discovery Platform has been designed to deconvolute the
characteristics of the tumor microenvironment related to clinical
outcomes. These discoveries are rapidly translated into optimized
multi-gene payloads of tumor modulators that can be delivered to
the tumor microenvironment for specific indications, disease
stages, and rationally designed therapeutic combinations. In 2022,
the Company announced a discovery partnership with the University
of Pennsylvania Center for Cellular Immunotherapies to create new
viral immunotherapies that could enhance the efficacy of chimeric
antigen receptor T cell (CAR-T) therapy in solid tumors. During the
Society for Immunotherapy of Cancer (SITC) 2023 Annual Meeting and
the 2023 International Oncolytic Virus Conference, Candel presented
encouraging data on the first candidate from this platform, Alpha
201-macro-1, which was designed to interfere with the CD47/SIRP1a
pathway, in mouse models of breast cancer and lung cancer.
About Candel Therapeutics
Candel is a clinical stage biopharmaceutical company focused on
developing off-the-shelf multimodal biological immunotherapies that
elicit an individualized, systemic anti-tumor immune response to
help patients fight cancer. Candel has established two clinical
stage multimodal biological immunotherapy platforms based on novel,
genetically modified adenovirus and herpes simplex virus (HSV) gene
constructs, respectively. CAN-2409 is the lead product candidate
from the adenovirus platform and is currently in ongoing clinical
trials in non-small cell lung cancer (NSCLC) (phase 2), borderline
resectable pancreatic cancer (phase 2), and localized,
non-metastatic prostate cancer (phase 2 and phase 3). CAN-3110 is
the lead product candidate from the HSV platform and is currently
in an ongoing investigator-sponsored phase 1 clinical trial in
recurrent high-grade glioma (HGG). Finally, Candel’s enLIGHTEN™
Discovery Platform is a systematic, iterative HSV-based discovery
platform leveraging human biology and advanced analytics to create
new viral immunotherapies for solid tumors.
For more information about Candel, visit: www.candeltx.com
Forward-Looking Statements
This press release includes certain disclosures that contain
“forward-looking statements” within the meaning of the Private
Securities Litigation Reform Act of 1995, as amended, including,
without limitation, express or implied statements regarding the
timing and advancement of development programs, including the
timing and availability of announcement of the second candidate
from the enLIGHTEN™ Discovery Platform. The words “may,” “will,”
“could,” “would,” “should,” “expect,” “plan,” “anticipate,”
“intend,” “believe,” “estimate,” “predict,” “project,” “potential,”
“continue,” “target” and similar expressions are intended to
identify forward-looking statements, although not all
forward-looking statements contain these identifying words. Any
forward-looking statements in this press release are based on
management’s current expectations and beliefs and are subject to a
number of risks, uncertainties and important factors that may cause
actual events or results to differ materially from those expressed
or implied by any forward-looking statements contained in this
press release, including, without limitation, those risks and
uncertainties related to the timing and advancement of development
programs; expectations regarding the therapeutic benefit of the
Company’s programs; that final data from our pre-clinical studies
and completed clinical trials may differ materially from reported
interim data from ongoing studies and trials; the Company’s ability
to efficiently discover and develop product candidates; the
Company’s ability to obtain and maintain regulatory approval of
product candidates; the Company’s ability to maintain its
intellectual property; the implementation of the Company’s business
model, and strategic plans for the Company’s business and product
candidates, and other risks identified in the Company’s SEC
filings, including the Company’s most recent Quarterly Report on
Form 10-Q filed with the SEC, and subsequent filings with the SEC.
The Company cautions you not to place undue reliance on any
forward-looking statements, which speak only as of the date they
are made. The Company disclaims any obligation to publicly update
or revise any such statements to reflect any change in expectations
or in events, conditions or circumstances on which any such
statements may be based, or that may affect the likelihood that
actual results will differ from those set forth in the
forward-looking statements. Any forward-looking statements
contained in this press release represent the Company’s views only
as of the date hereof and should not be relied upon as representing
its views as of any subsequent date.
Media ContactAljanae ReynoldsDirectorWheelhouse
Life Science Advisorsareynolds@wheelhouselsa.com
Investor ContactSylvia
WheelerPrincipalWheelhouse Life Science
Advisorsswheeler@wheelhouselsa.com
Candel Therapeutics (NASDAQ:CADL)
Graphique Historique de l'Action
De Avr 2024 à Mai 2024
Candel Therapeutics (NASDAQ:CADL)
Graphique Historique de l'Action
De Mai 2023 à Mai 2024